Special Issue "Cardiovascular Disease and Hemodialysis"
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2415
Interests: cardiovascular disease among hemodialysis patients
Chronic kidney disease (CKD) is a global health problem with an estimated prevalence of 13.4%. It is strongly associated with cardiovascular disease and imposes huge medical and financial burdens on societies and healthcare systems. The increasing prevalence of CKD, with its dramatic influence on morbidity and cardiovascular disease and the increased risk of mortality among patients with CKD, emphasize the need for further research in this field.
Due to the increased life expectancy and treatment options for patients with CKD and associated comorbidities, the prevalence of patients with end-stage kidney disease who require renal replacement therapy is increasing. Currently, only about 3 million patients are receiving kidney replacement therapy for end-stage kidney disease worldwide, among the 10 million who would qualify for kidney replacement therapy. These numbers are expected to increase by 50% to 100% by 2030.
Hemodialysis is the most common renal replacement therapy worldwide and, as such, the increasing rate of cardiovascular disease in this unique and specific population is valuable. Cardiovascular disease is not only common but also fatal in this population. It is the leading cause of death among hemodialysis patients, accounting for about 40% to 50% of all deaths in this high-risk population.
In addition to the pronounced cardiovascular risks among hemodialysis patients, they are often being excluded from clinical trials, their pathophysiology is complicated and includes traditional risk factors that coexist with chronic kidney disease (e.g., diabetes, dyslipidemia and hypertension), as well as non-traditional risk-factors, such as malnutrition, inflammation and mineral bone disorder, which accelerate atherosclerosis and vascular calcifications. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative and the international guideline group, Kidney Disease Improving Global Outcomes, have highlighted the importance of early detection and treatment of cardiovascular disease in patients with CKD.
The purpose of this Special Issue in Medicina is to discuss matters associated with cardiovascular disease in hemodialysis patients, including pathophysiology, treatment options and outcomes. The scope of the Issue is deliberately broad to encourage coverage of a wide range of topics and perspectives related to the management of cardiovascular disease among hemodialysis patients.
Dr. Keren Cohen-Hagai
Dr. Moshe Shashar
Dr. Sydney Benchetrit
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular disease
- vascular calcifications
- chronic kidney disease
- mineral bone disorder
- end-stage kidney disease
- renal replacement therapy
- endothelial dysfunction